Grape King Bio Ltd (1707) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Grape King Bio Ltd TWD 147, price TWD 87.00, upside +68.7%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Grape King Bio Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 86.30 TWD – 185.50 TWD · fair‑value band 110.10 TWD – 183.50 TWD · the 87.00 TWD price screens below the 146.80 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Grape King Bio in your weekly email
Every Wednesday you see whether Grape King Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments.
Show more
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; and microbial fermentation for mushroom mycelium, probiotics, and enzymes. It also offers functional ingredients for intestinal care, immunity regulation, liver care, brain health, eye care, weight control, feminine health, sensual health care, and others. It serves pharmaceutical preparations, finished drugs, oral liquids, and beverages and health foods. The company was founded in 1969 and is headquartered in Taoyuan City, Taiwan.
Stock analysis
Grape King Bio Ltd (1707) currently trades at 87.00 TWD, while our model-based Fair Value estimate is 146.80 TWD, implying the stock looks roughly 40.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 192.23 TWD per share, and 20 of the 24 models we run sit above the 87.00 TWD price.
Bear case: the Asset-Based group reads lowest at 46.77 TWD, and 4 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 110.10 TWD (bear) to 183.50 TWD (bull), the price of 87.00 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Grape King Bio Ltd reported revenue of 10.3B TWD in FY2025 versus 9.8B TWD in FY2021, a compound +1.1%/yr. Reported net income was 1.2B TWD in FY2025, compounding −11.1%/yr from FY2021.
Key figures
Market cap 19.7B TWD (≈ $618M) · P/E ratio 10.6 · P/S ratio 1.27 · EPS (TTM) 8.17 TWD · Dividend yield 6.9% · Net margin 11.9% · Return on equity 15.6% · Return on assets (EBIT) 16.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 69%, 1707 screens cheaper than that median.
Fair Value models
Bear 110.10 TWDFair Value 146.80 TWDBull 183.50 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.59 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−8.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Start year 2020 (pandemic). Over 10 years: +3.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−10.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.2%
Dividend (yield on the price)6.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17% vs −4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 21%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −5.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside+69% · Top 25%
Profitability
Return on equity (TTM)16% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)12% · Above median
Operating margin (TTM)15% · Above median
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)6.9% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Grape King Bio Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1707
Frequently asked questions
Is Grape King Bio Ltd (1707) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 146.80 TWD versus a price of 87.00 TWD, about +69% upside (undervalued).
What is the fair value of 1707?
Our model-based fair value for Grape King Bio Ltd is 146.80 TWD (as of Sep 23, 2026), built from audited fundamentals. The current price: 87.00 TWD.
What is the quality score of 1707?
Grape King Bio Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Grape King Bio Ltd (1707)?
Our model-based price target is the fair value of 146.80 TWD (as of Sep 23, 2026) from 24 valuation models. Cautious scenario 110.10 TWD, optimistic scenario 183.50 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Grape King Bio Ltd stock forecast for 2026?
Our models put fair value at 146.80 TWD, about +69% upside versus a price of 87.00 TWD (undervalued). Cautious scenario 110.10 TWD, optimistic scenario 183.50 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Grape King Bio Ltd (1707)?
Grape King Bio Ltd reported trailing-twelve-month revenue of about 10.3B TWD (latest available figure, as of Sep 23, 2026).
Does Grape King Bio Ltd pay a dividend?
Grape King Bio Ltd currently shows a dividend yield of about 6.90% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Grape King Bio Ltd (1707)?
For today's price to be fair in a discounted-cash-flow model, Grape King Bio Ltd would have to grow free cash flow by -3.9 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.3 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of 1707 use?
Our models discount Grape King Bio Ltd at 10.3 %: a base by market capitalisation (small), damped by beta 0.21, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Grape King Bio Ltd that is -3.9 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Grape King Bio Ltd (1707) delivered so far?
Over the past 5 years revenue at Grape King Bio Ltd grew +2.3 % a year. The price currently implies -3.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Grape King Bio Ltd (1707) growing?
The median revenue growth in the sector is +2.8 % a year. That is the yardstick for the growth priced into Grape King Bio Ltd (-3.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Grape King Bio Ltd (1707)?
The free-cash-flow yield on the price is 8.81 %: that much free cash flow Grape King Bio Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Grape King Bio Ltd (1707)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Grape King Bio Ltd it is 146.80 TWD per share (as of Sep 23, 2026), against a price of 87.00 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Grape King Bio Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 1707 trades below its calculated fair value: price 87.00 TWD, fair value 146.80 TWD, a gap of about +69% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1707?
No. The price is what the market pays today (87.00 TWD); the fair value is what the company's own numbers justify (146.80 TWD). For Grape King Bio Ltd the two are 59.80 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Grape King Bio Ltd worth?
The market values Grape King Bio Ltd at about 19.7B TWD (market capitalisation, as of Sep 23, 2026). Per share that is 87.00 TWD; our models calculate a fair value of 146.80 TWD per share.
What do the bullish and bearish scenarios say about 1707?
Our models span a range for Grape King Bio Ltd: cautious scenario 110.10 TWD, base 146.80 TWD, optimistic 183.50 TWD per share (as of Sep 23, 2026, price 87.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1707?
Grape King Bio Ltd trades at a price-to-earnings ratio of 10.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 146.80 TWD is built from several models across several years. Other multiples: P/B 1.9, P/S 1.9, EV/EBITDA 6.1.
How solid is the balance sheet of Grape King Bio Ltd (1707)?
Balance-sheet figures for Grape King Bio Ltd (as of Sep 23, 2026): return on equity 15.6%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 1707 from its 52-week high?
Grape King Bio Ltd trades at 87.00 TWD, about 33% below its 52-week high of 130.00 TWD and 1% above the low of 86.30 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 146.80 TWD is for.
Which stocks are comparable to Grape King Bio Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Grape King Bio Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price 87.00 TWD, calculated fair value 146.80 TWD (+69%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1707 calculated?
We run Grape King Bio Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 146.80 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Grape King Bio Ltd currently trades 69 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Grape King Bio Ltd (1707)?
The closing price on Sep 24, 2026 was 87.00 TWD. Our model-based fair value is 146.80 TWD, about +69% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Grape King Bio Ltd right now?
The price is below even our cautious bear case (110.10 TWD). The market is more pessimistic than our downside scenario. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Grape King Bio Ltd (1707) come from?
Earnings per share at Grape King Bio Ltd grew −0.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +0.8 %, EBIT margin −1.2 %, tax rate −0.3 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Grape King Bio Ltd
How large is the market capitalisation of Grape King Bio Ltd (1707)?
The market capitalisation of Grape King Bio Ltd is 19.7B TWD (≈ $618M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Grape King Bio Ltd (1707)?
The price-to-sales ratio of Grape King Bio Ltd is 1.27 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Grape King Bio Ltd (1707)?
Earnings per share at Grape King Bio Ltd are 8.17 TWD (price ÷ EPS = P/E 10.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Grape King Bio Ltd (1707)?
The dividend yield of Grape King Bio Ltd is 6.9% (payout 73.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Grape King Bio Ltd (1707)?
The net margin of Grape King Bio Ltd is 11.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Grape King Bio Ltd (1707)?
The return on equity (ROE) of Grape King Bio Ltd is 15.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Grape King Bio Ltd (1707)?
On an EBIT basis the return on assets of Grape King Bio Ltd is 16.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Grape King Bio Ltd (1707)?
The operating margin of Grape King Bio Ltd is 14.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Grape King Bio Ltd (1707)?
Revenue at Grape King Bio Ltd is growing +1.1% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Grape King Bio Ltd (1707)?
Earnings per share at Grape King Bio Ltd are growing −16.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Grape King Bio Ltd (1707) hold?
Grape King Bio Ltd holds more cash than debt, 3.9B TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Grape King Bio Ltd in the live analysis
One click puts Grape King Bio Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
